The global orthobiologics market size reached US$ 5.4 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 7.3 Billion by 2027, exhibiting a growth rate (CAGR) of 5.27% during 2022-2027.
Orthobiologics are tissue-derived products made using substances that are naturally found in the body, such as carbohydrates, proteins, cells, and glycoproteins. They assist in reducing pain and inflammation, reversing debilitating effects of osteoarthritis, and facilitating the process of cartilage regeneration, tendon healing, ligament repairing, and bone formation. Some of the commonly utilized orthobiologic therapies are stem cells, platelet-rich plasma (PRP), autologous conditioned plasma (ACP), and bone marrow aspirate concentrate (BMAC). Amongst these, PRP is gaining traction across the globe as novel treatment modalities with minimal side effects in diverse musculoskeletal conditions. These conditions include rotator cuff tears, sub-acromial impingement, shoulder osteoarthritis, patellar tendinosis, lateral epicondylar tendinopathy, and knee osteoarthritis.
Orthobiologics Market Trends:
Orthobiologics aid in the quick recovery of sports-related injuries among professional and recreational athletes. The increasing participation of individuals in sports and physical activities represents one of the major factors influencing the market positively. Apart from this, rotator cuff tears can appear among older people due to degenerative changes in the body. This, in confluence with the growing geriatric population, is impelling the market growth. Moreover, the risk of developing osteoarthritis can be increased due to sedentary lifestyles, unhealthy dietary patterns, and the prevalence of chronic diseases. In addition, several orthobiologics utilized for invasive surgeries can be reimbursed under insurance coverage, which is strengthening the market growth. Furthermore, the growing awareness about the benefits associated with orthobiologic therapies, such as avoiding major invasive surgery like joint replacement and fast recovery time, is promoting their adoption over other surgical procedures. Besides this, the increasing number of orthopedic surgeries and the escalating demand for bioabsorbable implants for fracture fixation is contributing to the use of orthobiologics, such as autograft and allograft bone, and demineralized bone matrix, among the pediatric population.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global orthobiologics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, type, application and end user.
Breakup by Product:
- Demineralized Bone Matrix
- Bone Morphogenetic Protein
- Viscosupplementation Products
- Synthetic Bone Substitutes
Breakup by Type:
- Wrist and Shoulder
Breakup by Application:
- Osteoarthritis and Degenerative Arthritis
- Spinal Fusion
- Fracture Recovery
- Soft Tissue Injuries
- Maxillofacial and Dental Applications
Breakup by End User:
- Hospitals and Ambulatory Centers
- Research and Academic Institutes
- Dental Clinics and Facilities
- Orthopedic Clinics
Breakup by Region:
- North America
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Arthrex Inc, Globus Medical Inc., Integra LifeSciences, Johnson & Johnson, Medline Industries Inc., Medtronic plc, NuVasive Inc, Orthofix Medical Inc., Smith & Nephew plc, Stryker Corporation, Terumo Corporation, Wright Medical Group N.V. and Zimmer Biomet.
|Base Year of the Analysis
||Product, Type, Application, End User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Arthrex Inc, Globus Medical Inc., Integra LifeSciences, Johnson & Johnson, Medline Industries Inc., Medtronic plc, NuVasive Inc, Orthofix Medical Inc., Smith & Nephew plc, Stryker Corporation, Terumo Corporation, Wright Medical Group N.V. and Zimmer Biomet
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report:
- How has the global orthobiologics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global orthobiologics market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global orthobiologics market and who are the key players?
- What is the degree of competition in the industry?